PSQ53159







www.chusantoantonio.pt Porto, Portugal


Optimization of the administration method for lutetium (177Lu)oxodotride in the treatment of neuroendocrine tumors

L. Álvares¹, S. Brandão Madureira¹, D. Monteiro¹, P. Rocha² ¹ PharmD, ULS Santo António, Porto, Portugal ² PharmD and director of pharmaceutical services, ULS Santo António, Porto, Portugal

Why was it done?

Lutetium (177Lu) oxodotreotide

✓ Lutetium (¹⁷⁷Lu) oxodotreotide is indicated for **treating subtype 2 somatostatin**



receptor-positive (SSTR2) gastroenteropancreatic neuroendocrine tumors, welldifferentiated G1 and G2, progressive, inoperable or metastatic.

- \checkmark This radiopharmaceutical targets cells with SSTR2 overexpression, emitting radiation that causes cell death (figure 1).
- ✓ Initially, the Summary of Product Characteristics (SmPC) included the gravity method for intravenous administration (figure 2).
- \checkmark This method was adopted and optimized due to incidents during administration.

What was done?

Optimization of the administration method of lutetium (¹⁷⁷Lu) oxodotreotide to maximize the administered radioactivity and enhance protection for healthcare professionals.

How was it done?




Figure 1 – Simplistic model of the mechanism of action of lutetium (¹⁷⁷Lu) oxodotride (pink and orange).(Adapted from [2])

Method optimization

- ✓ Led to a **decreasing trend** in the remaining values of radiopharmaceuticals, ensuring the administration of the entire activity;
- Allows the reduction of the exposure of professionals;
- \checkmark Reduces the possibility of contamination due to the permanence of the radiopharmaceutical in the original vial (SmPC).

What next?

 \checkmark We aim to apply this optimized method in other treatments with the same radionuclide.

References

[1] Summary of Product Characteristics - Lutathera. [S.I.] : INFARMED, 2022. [2] Kasi PM, Maige CL, Shahjehan F, et al. A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Front Oncol. 2019;8:663. Published 2019 Jan 9. doi:10.3389/fonc.2018.00663

luisaaalvares.farmacia@chporto.min-saude.pt | sarabrandaomadureira.farmacia@chporto.min-saude.pt | dianamonteiro.farmacia@chporto.min-saude.pt | dianamonteiro.farmacia@chporto.min-saude.pt